NASDAQ: APLTApplied Therapeutics Inc Stock
$4.74-0.09 (-1.86%)
Updated Apr 18, 2024
APLT Price
$4.74
Fair Value Price
$1.18
Market Cap
$501.90M
52 Week Low
$0.93
52 Week High
$9.39
P/E
-3.34x
P/B
-29.27x
P/S
28.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.99M
Earnings
-$119.76M
Gross Margin
100%
Operating Margin
-1,198.47%
Profit Margin
-1,198.5%
Debt to Equity
-4.2
Operating Cash Flow
-$55M
Beta
1.22
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
APLT Overview
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APLT ($4.74) is overvalued by 302.26% relative to our estimate of its Fair Value price of $1.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
APLT ($4.74) is not significantly undervalued (302.26%) relative to our estimate of its Fair Value price of $1.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
APLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APLT due diligence checks available for Premium users.
Be the first to know about important APLT news, forecast changes, insider trades & much more!
APLT News
Valuation
APLT fair value
Fair Value of APLT stock based on Discounted Cash Flow (DCF)
Price
$4.74
Fair Value
$1.18
Overvalued by
302.26%
APLT ($4.74) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APLT ($4.74) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.34x
Industry
15.68x
Market
41.33x
APLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-29.27x
Industry
5.76x
APLT's financial health
Profit margin
Revenue
-$667.0k
Net Income
-$37.7M
Profit Margin
5,649%
APLT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
APLT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$54.8M
Liabilities
$72.0M
Debt to equity
-4.2
APLT's short-term liabilities ($71.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APLT's short-term assets ($54.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.0M
Investing
$0.0
Financing
$29.4M
APLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APLT vs Biotech Stocks
Applied Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.